Detection of RBM15-MKL1 fusion was useful for diagnosis and monitoring of minimal residual disease in infant acute megakaryoblastic leukemia

Akiko Takeda, Akira Shimada, Kazuko Hamamoto, Syuuji Yoshino, Tomoko Nagai, Yousuke Fujii, Mutsuko Yamada, Yoshimi Nakamura, Toshiyuki Watanabe, Yuki Watanabe, Yuko Yamamoto, Kanae Sakakibara, Megumi Oda, Tsuneo Morishima

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Acute megakaryocytic leukemia (AMKL) with t(l; 22)(pl3; ql3) is a distinct category of myeloid leukemia by WHO classification and mainly reported in infants and young children. Accurate diagnosis of this type of AMKL can be difficult, because a subset of patients have a bone marrow (BM) blast percentage of less than 20% due to BM fibrosis. Theref+ore, it is possible that past studies have underestimated this type of AMKL. We present here the case of a 4-month-old female AMKL patient who was diagnosed by presence of the RBM15-MKL1 (OTT-MAL) fusion transcript by RT-PCR. In addition, we monitored RBM15-MKL1 fusion at several time points as a marker of minimal residual disease (MRD), and found that it was continuously negative after the first induction chemotherapy even by nested RT-PCR. Detection of the RBM15-MKL1 fusion transcript thus seems to be useful for accurate diagnosis of AMKL with t(l; 22)(pl3; ql3). We recommend that the RBM15-MKL1 fusion transcript be analyzed for all suspected AMKL in infants and young children. Furthermore, monitoring of MRD using this fusion transcript would be useful in treatment of AMKL with t(l; 22)(pl3; ql3).

Original languageEnglish
Pages (from-to)119-123
Number of pages5
JournalActa Medica Okayama
Volume68
Issue number2
Publication statusPublished - 2014

Fingerprint

Leukemia, Megakaryoblastic, Acute
Residual Neoplasm
Fusion reactions
Monitoring
Bone
Chemotherapy
Ores
Polymerase Chain Reaction
Primary Myelofibrosis
Induction Chemotherapy
Myeloid Leukemia
Bone Marrow

Keywords

  • AMKL
  • Infant
  • OTT-MAL
  • RBM15-MKL1

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Detection of RBM15-MKL1 fusion was useful for diagnosis and monitoring of minimal residual disease in infant acute megakaryoblastic leukemia. / Takeda, Akiko; Shimada, Akira; Hamamoto, Kazuko; Yoshino, Syuuji; Nagai, Tomoko; Fujii, Yousuke; Yamada, Mutsuko; Nakamura, Yoshimi; Watanabe, Toshiyuki; Watanabe, Yuki; Yamamoto, Yuko; Sakakibara, Kanae; Oda, Megumi; Morishima, Tsuneo.

In: Acta Medica Okayama, Vol. 68, No. 2, 2014, p. 119-123.

Research output: Contribution to journalArticle

Takeda, A, Shimada, A, Hamamoto, K, Yoshino, S, Nagai, T, Fujii, Y, Yamada, M, Nakamura, Y, Watanabe, T, Watanabe, Y, Yamamoto, Y, Sakakibara, K, Oda, M & Morishima, T 2014, 'Detection of RBM15-MKL1 fusion was useful for diagnosis and monitoring of minimal residual disease in infant acute megakaryoblastic leukemia', Acta Medica Okayama, vol. 68, no. 2, pp. 119-123.
Takeda, Akiko ; Shimada, Akira ; Hamamoto, Kazuko ; Yoshino, Syuuji ; Nagai, Tomoko ; Fujii, Yousuke ; Yamada, Mutsuko ; Nakamura, Yoshimi ; Watanabe, Toshiyuki ; Watanabe, Yuki ; Yamamoto, Yuko ; Sakakibara, Kanae ; Oda, Megumi ; Morishima, Tsuneo. / Detection of RBM15-MKL1 fusion was useful for diagnosis and monitoring of minimal residual disease in infant acute megakaryoblastic leukemia. In: Acta Medica Okayama. 2014 ; Vol. 68, No. 2. pp. 119-123.
@article{53f3c6d3f21e48ce9612806e4bd7cd04,
title = "Detection of RBM15-MKL1 fusion was useful for diagnosis and monitoring of minimal residual disease in infant acute megakaryoblastic leukemia",
abstract = "Acute megakaryocytic leukemia (AMKL) with t(l; 22)(pl3; ql3) is a distinct category of myeloid leukemia by WHO classification and mainly reported in infants and young children. Accurate diagnosis of this type of AMKL can be difficult, because a subset of patients have a bone marrow (BM) blast percentage of less than 20{\%} due to BM fibrosis. Theref+ore, it is possible that past studies have underestimated this type of AMKL. We present here the case of a 4-month-old female AMKL patient who was diagnosed by presence of the RBM15-MKL1 (OTT-MAL) fusion transcript by RT-PCR. In addition, we monitored RBM15-MKL1 fusion at several time points as a marker of minimal residual disease (MRD), and found that it was continuously negative after the first induction chemotherapy even by nested RT-PCR. Detection of the RBM15-MKL1 fusion transcript thus seems to be useful for accurate diagnosis of AMKL with t(l; 22)(pl3; ql3). We recommend that the RBM15-MKL1 fusion transcript be analyzed for all suspected AMKL in infants and young children. Furthermore, monitoring of MRD using this fusion transcript would be useful in treatment of AMKL with t(l; 22)(pl3; ql3).",
keywords = "AMKL, Infant, OTT-MAL, RBM15-MKL1",
author = "Akiko Takeda and Akira Shimada and Kazuko Hamamoto and Syuuji Yoshino and Tomoko Nagai and Yousuke Fujii and Mutsuko Yamada and Yoshimi Nakamura and Toshiyuki Watanabe and Yuki Watanabe and Yuko Yamamoto and Kanae Sakakibara and Megumi Oda and Tsuneo Morishima",
year = "2014",
language = "English",
volume = "68",
pages = "119--123",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "2",

}

TY - JOUR

T1 - Detection of RBM15-MKL1 fusion was useful for diagnosis and monitoring of minimal residual disease in infant acute megakaryoblastic leukemia

AU - Takeda, Akiko

AU - Shimada, Akira

AU - Hamamoto, Kazuko

AU - Yoshino, Syuuji

AU - Nagai, Tomoko

AU - Fujii, Yousuke

AU - Yamada, Mutsuko

AU - Nakamura, Yoshimi

AU - Watanabe, Toshiyuki

AU - Watanabe, Yuki

AU - Yamamoto, Yuko

AU - Sakakibara, Kanae

AU - Oda, Megumi

AU - Morishima, Tsuneo

PY - 2014

Y1 - 2014

N2 - Acute megakaryocytic leukemia (AMKL) with t(l; 22)(pl3; ql3) is a distinct category of myeloid leukemia by WHO classification and mainly reported in infants and young children. Accurate diagnosis of this type of AMKL can be difficult, because a subset of patients have a bone marrow (BM) blast percentage of less than 20% due to BM fibrosis. Theref+ore, it is possible that past studies have underestimated this type of AMKL. We present here the case of a 4-month-old female AMKL patient who was diagnosed by presence of the RBM15-MKL1 (OTT-MAL) fusion transcript by RT-PCR. In addition, we monitored RBM15-MKL1 fusion at several time points as a marker of minimal residual disease (MRD), and found that it was continuously negative after the first induction chemotherapy even by nested RT-PCR. Detection of the RBM15-MKL1 fusion transcript thus seems to be useful for accurate diagnosis of AMKL with t(l; 22)(pl3; ql3). We recommend that the RBM15-MKL1 fusion transcript be analyzed for all suspected AMKL in infants and young children. Furthermore, monitoring of MRD using this fusion transcript would be useful in treatment of AMKL with t(l; 22)(pl3; ql3).

AB - Acute megakaryocytic leukemia (AMKL) with t(l; 22)(pl3; ql3) is a distinct category of myeloid leukemia by WHO classification and mainly reported in infants and young children. Accurate diagnosis of this type of AMKL can be difficult, because a subset of patients have a bone marrow (BM) blast percentage of less than 20% due to BM fibrosis. Theref+ore, it is possible that past studies have underestimated this type of AMKL. We present here the case of a 4-month-old female AMKL patient who was diagnosed by presence of the RBM15-MKL1 (OTT-MAL) fusion transcript by RT-PCR. In addition, we monitored RBM15-MKL1 fusion at several time points as a marker of minimal residual disease (MRD), and found that it was continuously negative after the first induction chemotherapy even by nested RT-PCR. Detection of the RBM15-MKL1 fusion transcript thus seems to be useful for accurate diagnosis of AMKL with t(l; 22)(pl3; ql3). We recommend that the RBM15-MKL1 fusion transcript be analyzed for all suspected AMKL in infants and young children. Furthermore, monitoring of MRD using this fusion transcript would be useful in treatment of AMKL with t(l; 22)(pl3; ql3).

KW - AMKL

KW - Infant

KW - OTT-MAL

KW - RBM15-MKL1

UR - http://www.scopus.com/inward/record.url?scp=84899091955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899091955&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 119

EP - 123

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 2

ER -